John, E. R.
Abrams, K. R.
Brightling, C. E.
Sheehan, N. A.
Funding for this research was provided by:
National Institute for Health Research (DRF-2018-11-ST2-034, NI-SI-0512-10159)
Article History
Received: 31 May 2019
Accepted: 23 October 2019
First Online: 14 November 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: KRA has served as a paid consultant, providing methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON (Oxford Outcomes), Ipsen, Janssen, Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from ABPI, EFPIA, Pfizer and Sanofi. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.